[go: up one dir, main page]

WO2006034354A3 - Methodes pour le diagnostic et le traitement de tumeurs et de carcinomes a cellules renales sporadiques associes a la maladie de von hippel-lindau (vhl), d'autres tumeurs et lesions non tumorales homologues sporadiques de la maladie de vhl qui co-expriment l'epo et le recepteur de l'epo - Google Patents

Methodes pour le diagnostic et le traitement de tumeurs et de carcinomes a cellules renales sporadiques associes a la maladie de von hippel-lindau (vhl), d'autres tumeurs et lesions non tumorales homologues sporadiques de la maladie de vhl qui co-expriment l'epo et le recepteur de l'epo Download PDF

Info

Publication number
WO2006034354A3
WO2006034354A3 PCT/US2005/033850 US2005033850W WO2006034354A3 WO 2006034354 A3 WO2006034354 A3 WO 2006034354A3 US 2005033850 W US2005033850 W US 2005033850W WO 2006034354 A3 WO2006034354 A3 WO 2006034354A3
Authority
WO
WIPO (PCT)
Prior art keywords
vhl
tumors
sporadic
epo
cell carcinoma
Prior art date
Application number
PCT/US2005/033850
Other languages
English (en)
Other versions
WO2006034354A9 (fr
WO2006034354A2 (fr
Inventor
Zhengping Zhuang
Alexander Vortmeyer
Irina Lubensky
Edward Oldfield
Stefan Frank
Barbara Ikejiri
Tim Vogel
Youn-Soo Lee
Original Assignee
Us Gov Health & Human Serv
Zhengping Zhuang
Alexander Vortmeyer
Irina Lubensky
Edward Oldfield
Stefan Frank
Barbara Ikejiri
Tim Vogel
Youn-Soo Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Zhengping Zhuang, Alexander Vortmeyer, Irina Lubensky, Edward Oldfield, Stefan Frank, Barbara Ikejiri, Tim Vogel, Youn-Soo Lee filed Critical Us Gov Health & Human Serv
Publication of WO2006034354A2 publication Critical patent/WO2006034354A2/fr
Publication of WO2006034354A9 publication Critical patent/WO2006034354A9/fr
Publication of WO2006034354A3 publication Critical patent/WO2006034354A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne le diagnostic de la maladie de von Hippel-Lindau (VHL) et de carcinomes à cellules rénales sporadiques, ainsi que d'autres tumeurs homologues sporadiques associées à la maladie de VHL par détection d'EPO et de récepteurs d'EPO dans lesdites tumeurs et des tissus kystiques prélevés sur des patients, en particulier sur des patients souffrant de la maladie de VHL ou présentant un risque de développer cette maladie. L'invention concerne également le traitement de patients souffrant de ces tumeurs, kystes et lésions non tumorales.
PCT/US2005/033850 2004-09-20 2005-09-20 Methodes pour le diagnostic et le traitement de tumeurs et de carcinomes a cellules renales sporadiques associes a la maladie de von hippel-lindau (vhl), d'autres tumeurs et lesions non tumorales homologues sporadiques de la maladie de vhl qui co-expriment l'epo et le recepteur de l'epo WO2006034354A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61161604P 2004-09-20 2004-09-20
US60/611,616 2004-09-20

Publications (3)

Publication Number Publication Date
WO2006034354A2 WO2006034354A2 (fr) 2006-03-30
WO2006034354A9 WO2006034354A9 (fr) 2006-08-24
WO2006034354A3 true WO2006034354A3 (fr) 2006-10-12

Family

ID=36090654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033850 WO2006034354A2 (fr) 2004-09-20 2005-09-20 Methodes pour le diagnostic et le traitement de tumeurs et de carcinomes a cellules renales sporadiques associes a la maladie de von hippel-lindau (vhl), d'autres tumeurs et lesions non tumorales homologues sporadiques de la maladie de vhl qui co-expriment l'epo et le recepteur de l'epo

Country Status (1)

Country Link
WO (1) WO2006034354A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065792A2 (fr) 2008-12-04 2010-06-10 Curna, Inc. Traitement de maladies liées à l'érythropoïétine (epo) par inhibition d'un transcrit antisens naturel de l'epo
CN110066874A (zh) * 2019-04-26 2019-07-30 复旦大学附属华山医院 血管母细胞瘤分型诊断试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NOGUCHI YUMI ET AL: "Gene expression of erythropoietin in renal cell carcinoma", INTERNAL MEDICINE (TOKYO), vol. 38, no. 12, December 1999 (1999-12-01), pages 991 - 994, XP002390198, ISSN: 0918-2918 *
VORTMEYER ALEXANDER O ET AL: "Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease.", CANCER RESEARCH, vol. 63, no. 21, 1 November 2003 (2003-11-01), pages 7051 - 7055, XP002390195, ISSN: 0008-5472 *
WESTENFELDER CHRISTOF ET AL: "Erythropoietin stimulates proliferation of human renal carcinoma cells", KIDNEY INTERNATIONAL, vol. 58, no. 2, August 2000 (2000-08-01), pages 647 - 657, XP002390196, ISSN: 0085-2538 *
WIESENER MICHAEL S ET AL: "Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma", BLOOD, vol. 99, no. 10, 15 May 2002 (2002-05-15), pages 3562 - 3565, XP002390197, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2006034354A9 (fr) 2006-08-24
WO2006034354A2 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
CY1125258T1 (el) Νεοι παραγοντες απεικονισης για ανιχνευση νευρολογικης δυσλειτουργιας
WO2007109236A3 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2005001092A3 (fr) Compositions et procedes pour diagnostiquer et traiter le cancer
WO2008010101A3 (fr) Anticorps antagoniste destiné au traitement du cancer
WO2007142711A3 (fr) Compositions et procédés de diagnostic et de traitement du cancer
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2008091641A3 (fr) Compositions et procédés utilisés pour le diagnostic et le traitement du cancer
WO2006090389A3 (fr) Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
WO2010005567A3 (fr) Agents de liaison de récepteur notch1 et procédés d'utilisation
WO2008146309A3 (fr) Variantes génétiques sur les chr 5p12 et 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2009117277A3 (fr) Combinaisons de conjugués anticorps anti-her2-médicament et d’agents chimiothérapiques, et procédés d’utilisation
WO2007062138A3 (fr) Procedes et compositions pour le traitement de maladies ciblant la prominin-1(cd133) humaine
IL155611A0 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2010063701A3 (fr) Procédé d'imagerie in vivo
EP2412728A3 (fr) Procédés de traitement et de diagnostic et compositions ciblant 4IG-B7-H3 et son récepteur de cellules NK correspondant
WO2001073030A3 (fr) Compositions et methodes de diagnostic, de surveillance, de determination du stade, de representation et de traitement du cancer du colon
WO2007076294A3 (fr) Méthode pour dépister l'activité du récepteur smoothened afin d’identifier des agents de modulation therapeutique ou de diagnostiquer une maladie
WO2005055936A3 (fr) Procedes d'elimination de cellules tumorales par ciblage d'antigene interne expose sur des cellules tumorales apoptotiques
Hartimath et al. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
EP1667716A4 (fr) Mise en evidence l'expression surfacielle du cd44 par l'intermediaire de la cytotoxicite de cellules
WO2007107774A3 (fr) Nouvelles méthodes de diagnostic et de traitement
WO2006034354A3 (fr) Methodes pour le diagnostic et le traitement de tumeurs et de carcinomes a cellules renales sporadiques associes a la maladie de von hippel-lindau (vhl), d'autres tumeurs et lesions non tumorales homologues sporadiques de la maladie de vhl qui co-expriment l'epo et le recepteur de l'epo
WO2004094612A3 (fr) Anticorps monoclonaux specifiques de cancer
Saif et al. Gastrointestinal stromal tumors of the pancreas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase